ITK and B-cell chronic lymphocytic leukemia: Therefore, it still remains to be elucidated whether ibrutinib-mediated alterations of the T-cell compartment in CLL patients are due to a direct inhibition of ITK in T-cells, or indirectly due to the reduction of CLL tumor burden by ibrutinib and a subsequent normalization of the inflammatory milieu [101–103, 106–109].